Unusual Machines Grants CEO Warrants, Execs Get Stock Options

What Happened

• On July 24, 2026, Unusual Machines, Inc. announced that its Compensation Committee approved a grant of warrants to purchase 5,000,000 shares to CEO Dr. Allan Evans. The warrants expire July 24, 2031, have an exercise price of $25.00 per share, and will vest in five tranches of 1,000,000 shares each when the company’s common stock hits successive 20-day average price targets of $25, $40, $60, $80, and $100.
• The Committee also approved five-year stock options for other executives: 525,000 options to President Andrew Camden, 375,000 to CFO Brian Hoff, and 375,000 to CRO Stacy Wright (total 1,275,000 options). The options have an exercise price of $19.36 per share and vest in 12 equal quarterly installments over three years, subject to continued employment.
• In consideration of the warrant grant, Dr. Evans agreed to waive all cash compensation from the company following December 31, 2026. The CEO warrant grant is subject to shareholder approval.

Key Details

• Warrants to CEO: 5,000,000 shares; exercise price $25.00; expire July 24, 2031; vest on achieving five price targets (20-day avg).
• Executive options: 525,000 (Camden), 375,000 (Hoff), 375,000 (Wright); total 1,275,000; exercise price $19.36; five-year term; vest quarterly over 3 years.
• Compensation change: CEO to waive all cash pay after 12/31/2026 as consideration for the warrant grant.
• Shareholder approval required for the CEO warrant grant.

Why It Matters

• These awards materially change potential future dilution: if all warrants and options were exercised, up to 6,275,000 new shares could be issued. That could affect existing shareholders’ percentage ownership and per-share metrics.
• The CEO warrants are performance-based (stock-price hurdles), aligning executive upside with higher market valuation; the other grants are time-based, tying retention to multi-year employment.
• Investors should note the exercise prices ($25.00 for warrants, $19.36 for options) and the required shareholder vote for the CEO warrants when assessing potential dilution and management incentives.